Absorb GT1
Device
Abbott Laboratories
Total Payments
$1.4M
Transactions
2,503
Doctors
1,061
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3,750 | 1 | 0 |
| 2023 | $355,477 | 8 | 0 |
| 2021 | $780,161 | 451 | 90 |
| 2020 | $157.98 | 4 | 4 |
| 2019 | $51,953 | 47 | 14 |
| 2018 | $46,988 | 60 | 35 |
| 2017 | $207,904 | 1,932 | 951 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 297 | 74.7% |
| Consulting Fee | $245,743 | 190 | 17.0% |
| Food and Beverage | $94,334 | 1,994 | 6.5% |
| Travel and Lodging | $25,063 | 18 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $500.00 | 1 | 0.0% |
| Education | $242.32 | 3 | 0.0% |
Payments by Type
Research
$1.1M
297 transactions
General
$365,883
2,206 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions. | Abbott Laboratories | $705,055 | 0 |
| ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) | Abbott Laboratories | $355,077 | 0 |
| Absorb PAS | Abbott Laboratories | $8,126 | 0 |
| BVS in BTK A retrospective study | Abbott Laboratories | $5,000 | 0 |
| A Clinical Evaluation ofAbsorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions | Abbott Laboratories | $3,750 | 0 |
| A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions | Abbott Laboratories | $3,100 | 0 |
| ABSORB II Randomized Controlled Trial (ABSORB II) | Abbott Laboratories | $400.00 | 0 |
Top Doctors Receiving Payments for Absorb GT1 — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Robb Kociol | — | Plymouth, MA | $1,488 | 2 |
| , MD | Cardiovascular Disease | Orlando, FL | $1,400 | 1 |
| , M.D | Cardiovascular Disease | Durham, NC | $1,389 | 2 |
| , M.D | Vascular & Interventional Radiology | Orange, CA | $1,200 | 1 |
| , M.D | Neurology | Brighton, MA | $1,000 | 1 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Boston, MA | $1,000 | 1 |
| , M.D., PH.D | Cardiovascular Disease | Bronx, NY | $1,000 | 1 |
| , MD | Internal Medicine | Boston, MA | $1,000 | 2 |
| , M.D | Cardiovascular Disease | New York, NY | $1,000 | 1 |
| , MD | Internal Medicine | Boston, MA | $674.24 | 8 |
| , M.D | Cardiovascular Disease | Durham, NC | $650.00 | 2 |
| , MD | Vascular Surgery | Los Angeles, CA | $644.71 | 6 |
| , D.O | Cardiovascular Disease | Wichita, KS | $595.00 | 11 |
| , M.D | Internal Medicine | Saint Louis, MO | $475.50 | 8 |
| , MD | Internal Medicine | Corpus Christi, TX | $426.11 | 20 |
| , M.D | Cardiovascular Disease | Grand Junction, CO | $407.42 | 10 |
| , M.D | Internal Medicine | Cincinnati, OH | $389.04 | 3 |
| , MD | Cardiovascular Disease | Charlotte, NC | $383.33 | 9 |
| , MD | Cardiovascular Disease | Houston, TX | $380.18 | 5 |
| , MD | Cardiovascular Disease | Evansville, IN | $374.83 | 12 |
| , M.D | Cardiovascular Disease | Seattle, WA | $374.00 | 4 |
| , M.D | Cardiovascular Disease | Saint Louis, MO | $367.22 | 3 |
| , M.D | Cardiovascular Disease | Roseville, MI | $339.53 | 6 |
| , MD | Cardiovascular Disease | New Iberia, LA | $328.62 | 5 |
| , MD | Internal Medicine | Boca Raton, FL | $312.97 | 9 |
Ad
Manufacturing Companies
- Abbott Laboratories $1.4M
Product Information
- Type Device
- Total Payments $1.4M
- Total Doctors 1,061
- Transactions 2,503
About Absorb GT1
Absorb GT1 is a device associated with $1.4M in payments to 1,061 healthcare providers, recorded across 2,503 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2017 to 2024. In 2024, $3,750 was paid across 1 transactions to 0 doctors.
The most common payment nature for Absorb GT1 is "Unspecified" ($1.1M, 74.7% of total).
Absorb GT1 is associated with 7 research studies, including "A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions." ($705,055).